Prescribing information

 

Prescribing information

_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Discover on-demand webinars from UK and international ophthalmology experts.

Contact your Novartis representative if you would like to express interest in registering for future events.
 

Click here for LUCENTIS®(ranibizumab) prescribing information
 

 

Introducing Beovu: An innovation in wet AMD

 

 

Current challenges & unmet needs in wet AMD

Mrs Deepali Varma, Consultant Ophthalmologist & Lead clinician macular service at Sunderland Eye Infirmary, discusses challenges physicians currently face and the impact this disease has had on ophthalmology patients seeking treatment.

 

 

Why fluid matters in wet AMD

Mrs Deepali Varma, Consultant Ophthalmologist & Lead clinician macular service at Sunderland Eye Infirmary, discusses how to judge if wet AMD is active, types of fluid and management for patients with wet AMD.

 

 

 

 

Introduction to a new generation anti-VEGF

Robin Hamilton, Honorary Senior Lecturer, Institute of Ophthalmology, and Consultant Ophthalmic Surgeon at Moorfields Eye Hospital, gives an overview of Beovu’s two pivotal trials in adults with wet AMD – the HAWK and HARRIER studies.

 

 

Experiencing Beovu: Real-world perspectives

 

 

Optimising wet AMD Treatment

Dr Rishi P. Singh, Staff surgeon at the Cleveland Clinic and assistant professor of the Lerner College Cleveland, Ohio, USA, provides an overview of the evolution of wet AMD treatment and his approach to disease management, including the importance of early diagnosis and imaging.

 

 

First experience in Germany: Patient cases and implementation

Professor Armin Wolf, Professor of Ophthalmology and Head of Service at the University of Ulm, provides valuable insights into how Beovu is being used in clinics in Germany and early treatment outcomes in patients.

 

 

 

 

First experience in USA: Patient cases and implementation

Dr Rishi P. Singh provides valuable insights into how Beovu is used in clinics in the USA and treatment outcomes in patients.

 

 

Indication: Beovu is indicated in adults for the treatment of neovascular (wet) AMD.1

AMD, age-related macular degeneration.

Reference

  1. Beovu Summary of Product Characteristics, 2020.
     
UK | December 2020 | 101154
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]